TREATMENT PATTERN IN PATIENTS WITH ADVANCED BREAST CANCER AFTER CDK4/6I FAILURE IN CHINA
Author(s)
Shouang Wang, Master Candidate, Boyang Li, Master Candidate, Xiaoning He, PhD, Jing Wu, PhD;
Tianjin University, Tianjin, China
Tianjin University, Tianjin, China
OBJECTIVES: The optimal treatment strategy after progression on endocrine therapy (ET) plus a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) remains unclear in China and worldwide. This study aimed to describe real-world treatment patterns and disease burden among patients with advanced breast cancer (ABC) after CDK4/6i failure in China.
METHODS: This retrospective cohort study used a multicenter hospital electronic medical record database from nine representative hospitals across nine provinces with geographic and socioeconomic diversity, covering January 2020 to September 2024. We included patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative ABC who received CDK4/6i therapy between January 2020 and September 2023. Patient characteristics were summarized, and longitudinal treatment trajectories over 1-year follow-up were mapped using a Sankey diagram; healthcare resource utilization and costs were assessed.
RESULTS: A total of 1,492 patients discontinued CDK4/6i; 99.7% were female, with a mean age of 54.8±14.6 years. Abemaciclib accounted for 85.7% of discontinuations (n=1,279) and the mean follow-up duration was 315.9±91.9 days. 16.6% of patients switched to another CDK4/6i, and 9.6% (n=143) received other targeted therapies, most commonly everolimus (4.4%) and chidamide (3.6%). In addition, 19.5% (n=88) received no further anti-tumor therapy. Among patients continuing treatment, the most common therapy in first subsequent line was ET (57.1%), followed by chemotherapy (26.9%) and switching to a different CDK4/6i (9.7%). In second line, chemotherapy (42.8%) and ET (25.2%) were the most frequently observed regimens. Mean number of treatment changes was 1.56.
CONCLUSIONS: In real-world practice, for patients with ABC after CDK4/6i failure, treatment choices appeared to deviate from guideline-recommended sequencing, with substantial reliance on conventional ET or chemotherapy. Around one-fifth of patients received no further anti-tumor therapy, suggesting limited feasible options. Current strategies may not adequately address unmet needs, highlighting an urgent need for more accessible and effective targeted therapies to improve long-term outcomes.
METHODS: This retrospective cohort study used a multicenter hospital electronic medical record database from nine representative hospitals across nine provinces with geographic and socioeconomic diversity, covering January 2020 to September 2024. We included patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative ABC who received CDK4/6i therapy between January 2020 and September 2023. Patient characteristics were summarized, and longitudinal treatment trajectories over 1-year follow-up were mapped using a Sankey diagram; healthcare resource utilization and costs were assessed.
RESULTS: A total of 1,492 patients discontinued CDK4/6i; 99.7% were female, with a mean age of 54.8±14.6 years. Abemaciclib accounted for 85.7% of discontinuations (n=1,279) and the mean follow-up duration was 315.9±91.9 days. 16.6% of patients switched to another CDK4/6i, and 9.6% (n=143) received other targeted therapies, most commonly everolimus (4.4%) and chidamide (3.6%). In addition, 19.5% (n=88) received no further anti-tumor therapy. Among patients continuing treatment, the most common therapy in first subsequent line was ET (57.1%), followed by chemotherapy (26.9%) and switching to a different CDK4/6i (9.7%). In second line, chemotherapy (42.8%) and ET (25.2%) were the most frequently observed regimens. Mean number of treatment changes was 1.56.
CONCLUSIONS: In real-world practice, for patients with ABC after CDK4/6i failure, treatment choices appeared to deviate from guideline-recommended sequencing, with substantial reliance on conventional ET or chemotherapy. Around one-fifth of patients received no further anti-tumor therapy, suggesting limited feasible options. Current strategies may not adequately address unmet needs, highlighting an urgent need for more accessible and effective targeted therapies to improve long-term outcomes.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
RWD57
Topic
Real World Data & Information Systems
Topic Subcategory
Health & Insurance Records Systems, Reproducibility & Replicability
Disease
SDC: Oncology